All (n = 411) | Survivor (n = 333) | Non-survivor (n = 78) | P value Survivor versus non-survivor | |
---|---|---|---|---|
Age (years) | 80.1 ± 7.1 | 79.9 ± 7.2 | 81.0 ± 6.2 | 0.24 |
Female sex | 46.0% (189/411) | 46.3 (154/333) | 44.9 (35/78) | 0.83 |
BMI (kg/m2) | 26.5 ± 4.5 | 26.7 ± 4.6 | 25.7 ± 4.0 | 0.09 |
Body surface area (m2) | 1.80 ± 0.20 | 1.85 ± 0.20 | 1.84 ± 0.21 | 0.63 |
Systolic blood pressure (mmHg) | 141 ± 23 | 142 ± 22 | 142 ± 29 | 0.91 |
Diastolic blood pressure (mmHg) | 75 ± 12 | 74 ± 12 | 76 ± 13 | 0.64 |
Creatinine clearance (ml/min) | 60 (IQR 28) | 62 (QR 28) | 57 (IQR 27) | 0.25 |
Eurolog II (%) | 3.1 (IQR 3.4) | 2.9 (IQR 2.8) | 4.3 (IQR 5.7) | 0.0001 |
Hemodialysis | 1.0% (4/411) | 0.9% (3/333) | 1.3% (1/78) | 0.76 |
Previous myocardial infarction | 12.0% (46/385) | 10.4% (32/309) | 18.4% (14/76) | 0.05 |
Hypertension | 72.5% (271/374) | 73.8% (222/301) | 67.1% (49/73) | 0.26 |
COPD | 15.8% (65/411) | 15.0% (50/333) | 19.2% (15/78) | 0.36 |
PAD | 14.4% (59/410) | 13.3% (44/332) | 19.2% (15/78) | 0.18 |
DM2 | 18.3% (68/372) | 18.3% (55/301) | 18.3% (13/71) | 0.99 |
NYHA I–II | 22.5% (92/409) | 24.5% (81/331) | 14.1% (11/78) | 0.0001 |
NYHA III | 68.7% (281/409) | 69.5% (230/331) | 65.4% (51/78) | |
NYHA IV | 8.8% (36/409) | 6.0% (20/331) | 20.5% (16/78) | |
Medications | ||||
Statins | 59.0% (222/379) | 59.7% (181/303) | 56.2% (41/73) | 0.58 |
Beta blockers | 50.1% (204/407) | 48.6% (161/331) | 56.6% (43/76) | 0.21 |
Calcium antagonists | 25.0% (102/408) | 26.2% (87/332) | 19.7% (15/76) | 0.24 |
ACE inhibitors/ARB | 33.3% (136/408) | 34.0% (113/332) | 30.3% (23/76) | 0.53 |
Anticoagulant treatment | 26.2% (107/408) | 24.4% (81/332) | 34.2% (27/76) | 0.08 |
Thrombocyte inhibitors | 40.7% (166/408) | 42.8% (142/332) | 31.6% (24/76) | 0.07 |
Valve characteristics | ||||
Valve type | ||||
Edwards S3 | 80.3% (330/411) | 79.9% (266/333) | 82.1% (64/78) | 0.73 |
Edwards XT | 9.7% (40/411) | 9.3% (31/333) | 11.5% (9/78) | |
Evolute | 1.9% (8/411) | 2.4% (8/333) | 0% (0/78) | |
Lotus | 1.7% (7/411) | 1.8% (6/333) | 1.3% (1/78) | |
Others | 6.4% (26/411) | 6.6% (22/333) | 5.1% (4/78) | |
Valve size (mm) | 26.1 ± 2.4 | 26.0 ± 2.4 | 26.5 ± 2.3 | 0.10 |